Keyphrases
Placebo
100%
Randomized Placebo-controlled Trial
100%
Long-acting β2-agonist
100%
Vilanterol
100%
Once-daily
80%
Forced Expiratory Volume in 1 Second (FEV1)
60%
Clinically Significant
40%
Weighted Mean
40%
Trough FEV1
40%
Vital Signs
20%
Adverse Events
20%
Blood Glucose
20%
Dose Effect
20%
Treatment Duration
20%
Response Rate
20%
Combination Therapy
20%
Low Incidence
20%
Heart Rate
20%
Asthma
20%
Dose-response
20%
Moderate to Severe
20%
Days of Treatment
20%
Pulse Rate
20%
Safety Assessment
20%
Tolerability
20%
Lung Function
20%
Change from Baseline
20%
Treatment-related Adverse Events
20%
Randomized Double-blind
20%
Intent-to-treat
20%
Serious Adverse Events
20%
Clinical Laboratory Test
20%
Inhaled Corticosteroids
20%
Severe COPD
20%
Treatment Difference
20%
QT Interval
20%
Trial Registries
20%
Serum Potassium
20%
Fridericia Formula
20%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Chronic Obstructive Lung Disease
100%
Vilanterol
100%
Adverse Event
50%
Combination Therapy
16%
Asthma
16%
Tolerability
16%
Safety Assessment
16%
Isotopes of Potassium
16%
Vilanterol Trifenatate
16%